<?xml version="1.0" encoding="UTF-8"?>
<p>Additional groups were IP- and IC-inoculated with prototype or mutant BgV chimeras. Protoype BgV
 <sub>C-CG</sub>/WNV-prME replicated in 17% of IP-inoculated mice and in all IC-inoculated mice as shown by seroconversion (
 <xref ref-type="fig" rid="pntd.0008166.g005">Fig 5A and 5B</xref>), however, no clinical signs of disease and no neutralising antibodies were recorded for any BgV
 <sub>C-CG</sub>/WNV-prME-inoculated mice (
 <xref ref-type="fig" rid="pntd.0008166.g005">Fig 5Aâ€“5C</xref>). Nevertheless, the ability of BgV
 <sub>C-CG</sub>/WNV-prME to establish an infection is enhanced when compared to BgV
 <sub>C-CG</sub>.
</p>
